We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
Turnover
16.03%
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
5.4
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
551
PBF Energy
PBF
$10.3B
| $10.9M | 0.02% |
503,804
+486,189
| +2,760% | +$9.24M |
2015 Q3
39 quarters
|
|
552
Insmed
INSM
$21.7B
| $10.9M | 0.02% |
108,385
-84,258
| -44% | -$6.44M |
2023 Q3
7 quarters
|
|
553
AstraZeneca
AZN
$259B
| $10.8M | 0.02% |
77,504
-20,559
| -21% | -$2.88M |
2013 Q2
48 quarters
|
|
554
DXC Technology
DXC
$2.2B
| $10.8M | 0.02% |
706,339
+30,037
| +4% | +$462K |
2017 Q2
32 quarters
|
|
555
Masco
MAS
$14.3B
| $10.8M | 0.02% |
167,287
-29,325
| -15% | -$1.85M |
2013 Q2
48 quarters
|
|
556
Leonardo DRS
DRS
$9.47B
| $10.7M | 0.02% |
+229,747
| New | +$9.23M |
2025 Q2
0 quarters
|
|
557
Flex
FLEX
$36.4B
| $10.6M | 0.02% |
212,948
-13,643
| -6% | -$532K |
2023 Q1
9 quarters
|
|
558
JELD-WEN Holding
JELD
$118M
| $10.6M | 0.02% |
2,707,888
+1,313,463
| +94% | +$5.85M |
2020 Q3
19 quarters
|
|
559
Turning Point Brands
TPB
$1.21B
| $10.6M | 0.02% |
139,569
-13,586
| -9% | -$924K |
2022 Q2
12 quarters
|
|
560
Helen of Troy
HELE
$691M
| $10.6M | 0.02% |
372,049
+186,433
| +100% | +$5.72M |
2013 Q2
48 quarters
|
|
561
Construction Partners
ROAD
$4.72B
| $10.5M | 0.02% |
98,463
+80,576
| +450% | +$7.53M |
2023 Q4
6 quarters
|
|
562
Aspen Aerogels
ASPN
$448M
| $10.5M | 0.02% |
+1,766,733
| New | +$10.2M |
2025 Q2
0 quarters
|
|
563
Choice Hotels
CHH
$4.81B
| $10.4M | 0.02% |
82,064
-51
| -0.1% | -$6.45K |
2017 Q2
32 quarters
|
|
564
FMC
FMC
$874M
| $10.4M | 0.02% |
248,239
-157,500
| -39% | -$6.26M |
2024 Q2
4 quarters
|
|
565
Elevance Health
ELV
$92.9B
| $10.3M | 0.02% |
26,602
-1,872
| -7% | -$753K |
2013 Q2
48 quarters
|
|
566
Arcutis Biotherapeutics
ARQT
$3.66B
| $10.3M | 0.02% |
737,369
-186
| -0% | -$2.61K |
2022 Q4
10 quarters
|
|
567
Murphy USA
MUSA
$10B
| $10.3M | 0.02% |
25,382
-11,567
| -31% | -$5.26M |
2013 Q3
47 quarters
|
|
568
Fortis
FTS
$27.9B
| $10.3M | 0.02% |
215,433
-5,103
| -2% | -$243K |
2016 Q4
34 quarters
|
|
569
MSC Industrial Direct
MSM
$7.3B
| $10.2M | 0.02% |
120,551
+34,357
| +40% | +$2.71M |
2013 Q2
48 quarters
|
|
570
Equinix
EQIX
$98.3B
| $10.2M | 0.02% |
12,875
-329
| -2% | -$279K |
2013 Q2
48 quarters
|
|
571
Smith Douglas Homes
SDHC
$87.7M
| $10.2M | 0.02% |
527,300
| – | – |
2024 Q1
5 quarters
|
|
572
Acadian Asset Management
AAMI
$3.29B
| $10.2M | 0.02% |
290,323
-19,486
| -6% | -$566K |
2024 Q3
3 quarters
|
|
573
Axalta
AXTA
$7.22B
| $10.1M | 0.02% |
340,728
-798,508
| -70% | -$24.9M |
2017 Q2
32 quarters
|
|
574
Comcast
CMCSA
$77.3B
| $10.1M | 0.02% |
281,616
-19,448
| -6% | -$673K |
2013 Q2
48 quarters
|
|
575
Medpace
MEDP
$17.5B
| $10M | 0.02% |
31,950
+9,893
| +45% | +$2.97M |
2017 Q1
33 quarters
|
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.